Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors

Active:	No
Cancer Type:	Lung Cancer Sarcoma Solid Tumor Unknown Primary	NCT ID:	NCT04526509
Trial Phases:	Phase I	Protocol IDs:	209012 (primary) NCI-2020-11491
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	GlaxoSmithKline
NCI Full Details:	http://clinicaltrials.gov/show/NCT04526509

Summary

This trial will evaluate the safety and efficacy of first time in human engineered T-cell
therapies, in participants with advanced tumors.

Objectives

This study is a master protocol. It has two sub studies registered as 209012 Sub Study 1
(NCT06048705) and 209012 Sub Study 2 (NCT05943990).

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.